2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Dermatologic
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Neoplasms
2
Interventions
pembrolizumab
95
Paclitaxel
86
Gemcitabine
84
Carboplatin
79
Surveys and Questionnaires
72
Docetaxel
61
Bevacizumab
61
Nivolumab
59
Cisplatin
59
Magnetic Resonance Spectroscopy
50
Blood Specimen Collection
50
Fluorouracil
48
Radiotherapy
47
Capecitabine
47
Irinotecan
40
Oxaliplatin
38
Erlotinib Hydrochloride
38
Biopsy
36
atezolizumab
35
Leucovorin
35
Pemetrexed
34
Standard of Care
32
Cetuximab
32
Specimen Handling
31
Trastuzumab
30
Radiosurgery
29
Ipilimumab
28
Cyclophosphamide
28
Interviews as Topic
27
olaparib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Aftercare
×
Tumor-Agnostic
×
Clear all
NCT02637349
2019-11-26
POST
Polaris Health Directions
Phase 2
Completed
200 enrolled
NCT02440737
2019-10-18
NEST
Vanderbilt-Ingram Cancer Center
Phase NA
Terminated
67 enrolled